Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2

With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and how a lead antibody candidate has been selected.

COVID-19 and antibodies

The mobilisation of the pharmaceutical industry to identify and develop therapeutics for patients with COVID-19 has led to a wide range of innovative treatments. One key class of biopharmaceuticals that have shown great potential is antibodies.

Recently, Adagio Therapeutics published data showing the success of its lead antibody candidate in vitro and in vivo. With a focus on ensuring success against variants of SARS-CoV-2, Walker explained how the researchers conducted pre-clinical studies to prove the new treatment is effective and why antibodies are vital for ending the pandemic.

    To read this article in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Agilent

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.